News | September 02, 2022
NATCO Pharma to sell stake in Nativita and assets of Pharma division
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
India has the second-largest number of adults with diabetes globally, after China
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Food-tech disruptor prepares to vastly scale dairy-identical, non-animal milk protein production in a pioneering sustainable industrial park in Denmark
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Subscribe To Our Newsletter & Stay Updated
